VolitionRx Limited (VNRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VolitionRx Limited on September 30, 2024. The filing reports a corporate governance event: the appointment of a new independent director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from six to seven members.
- New Appointment: Dr. Ethel Rubin was appointed as a Director effective September 30, 2024.
- Committee Assignments: Dr. Rubin was appointed to the Audit Committee and the Compensation Committee.
- Independence: The Board determined Dr. Rubin to be independent under SEC and NYSE American standards.
Compensation and Outlook
Dr. Rubin entered into an Independent Director Agreement with the following compensation terms:
- Cash Retainer: $10,840 per calendar quarter, commencing September 30, 2024.
- Equity Grant: 15,000 Restricted Stock Units (RSUs) under the 2015 Stock Incentive Plan.
- Vesting Schedule: The RSUs vest in three equal installments at 12, 24, and 36 months from the grant date.
Dr. Rubin's term expires at the 2025 annual meeting of stockholders, subject to future nomination and election. The Board cited her over 20 years of experience in healthcare innovation, commercialization, and strategy as the rationale for the appointment.
Investor Verification Checklist
- Verify Dr. Ethel Rubin's independence status and potential conflicts of interest via the full Independent Director Agreement.
- Confirm the impact of the new board member on the composition of the Audit and Compensation Committees.
- Review the press release (Exhibit 99.1) for additional strategic context regarding the appointment.
- Check subsequent filings (10-Q or 10-K) for financial performance data, as this 8-K contains no financial metrics.